pharmaceutical investing Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX for Injection
pharmaceutical investing Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
pharmaceutical investing Medexus Provides Business Update on GRAFAPEX for Injection, Capital Allocation, and Investor Conference Participation
pharmaceutical investing Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX for Injection
pharmaceutical investing Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
pharmaceutical investing Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX for Injection
pharmaceutical investing Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
pharmaceutical investing Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX for Injection
GoldInxs Advances Fishpot Toward Maiden Drill Program with New 3D IP Survey, Magnetic and Virtual DRILL Results
JAGUAR URANIUM REPORTS RARE EARTH OXIDES ASSOCIATED WITH URANIUM-PHOSPHATE-VANADIUM MINERALIZATION AT THE BERLIN ASSET IN COLOMBIA
Spartan Metals Receives BLM Approval for Seven Additional Drill Sites at its Tungstonia Claims, Nevada
